Current treatment of multiple sclerosis

被引：0

作者：

Gout, O. ^{[1
]}

Bensa, C. ^{[1
]}

Assouad, R. ^{[1
]}

机构：

[1] Fdn Ophtalmol A de Rothschild, Serv Neurol, F-75019 Paris, France

来源：

REVUE DE MEDECINE INTERNE | 2010年 / 31卷 / 08期

关键词：

Multiple sclerosis; Immunomodulatory drugs; Interferon beta; Glatiramer acetate; Mitoxantrone; Natalizumab; Cyclophosphamide; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; INTERFERON BETA-1A; DOUBLE-BLIND; CYCLOPHOSPHAMIDE; THERAPY; MULTICENTER; MITOXANTRONE; NATALIZUMAB; COMBINATION; DISABILITY;

D O I：

10.1016/j.revmed.2009.08.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since commercialisation of the first immunomodulatory drug (IMD) for multiple sclerosis (subcutaneous interferon beta-1b) in 1995, three new IMD have been on the market: two interferons (intramuscular interferon beta-1a and subcutaneous interferon beta-la) and glatiramer acetate. These four immunomodulatory drugs have a similar efficiency: they reduce by about 30% the relapse rate of treated patients compared to untreated patients. Their effect on disability is moderate mainly due to the reduced relapse rate. Lately, in 2002, mitoxantrone was approved for aggressive relapsing-remitting MS and in 2007 the first monoclonal antibody (natalizumab) was approved for active relapsing-remitting MS. (C) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：575 / 580

页数：6

共 35 条

[1]

[Anonymous], 2008, ARCH NEUROL-CHICAGO, V65, P1044, DOI 10.1001/archneurol.65.8.noc80042

[2]

BOZIC C, 2009, NEUROLOGY S, V3

[3] A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [J].

Brex, PA ;

Ciccarelli, O ;

O'Riordan, JI ;

Sailer, M ;

Thompson, AJ ;

Miller, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :158-164

[4]

Brodsky M, 2008, ARCH NEUROL-CHICAGO, V65, P727, DOI 10.1001/archneur.65.6.727

[5] How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? [J].

Brown, M. G. ;

Kirby, S. ;

Skedgel, C. ;

Fisk, J. D. ;

Murray, T. J. ;

Bhan, V. ;

Sketris, I. S. .

NEUROLOGY, 2007, 69 (15) :1498-1507

[6] Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].

Comi, G ;

Filippi, M ;

Barkhof, F ;

Durelli, L ;

Edan, G ;

Fernández, O ;

Hartung, HP ;

Seeldrayers, P ;

Sorensen, PS ;

Rovaris, M ;

Martinelli, V ;

Hommes, OR .

LANCET, 2001, 357 (9268) :1576-1582

[7]

COMI G, 2007, EUR CHARC FDN S IT F

[8]

COMI G, 2008, TREATMENT GLATIRAMER

[9]

Confavreux C., 2006, MCALPINES MULTIPLE S, DOI DOI 10.1016/B978-0-443-07271-0.50006-9

[10] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

← 1 2 3 4 →